CY1110156T1 - Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης - Google Patents

Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης

Info

Publication number
CY1110156T1
CY1110156T1 CY20101100582T CY101100582T CY1110156T1 CY 1110156 T1 CY1110156 T1 CY 1110156T1 CY 20101100582 T CY20101100582 T CY 20101100582T CY 101100582 T CY101100582 T CY 101100582T CY 1110156 T1 CY1110156 T1 CY 1110156T1
Authority
CY
Cyprus
Prior art keywords
ylamine
benzothiiazol
tetrahydro
substituted compounds
substituted
Prior art date
Application number
CY20101100582T
Other languages
English (en)
Inventor
Stefan Oberbörsch
Corinna Sundermann
Bernd Sundermann
Edward Bijsterveld
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1110156T1 publication Critical patent/CY1110156T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Η παρούσα εφεύρεση αφορά υποκατεστημένες ενώσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμίνης, μεθόδους για την παρασκευή τους, φάρμακα που περιέχουν τις ενώσεις αυτές, καθώς και τη χρησιμοποίηση των ενώσεων αυτών για την παρασκευή φαρμάκων.
CY20101100582T 2004-02-11 2010-06-25 Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης CY1110156T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004006808A DE102004006808A1 (de) 2004-02-11 2004-02-11 Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen
EP05715296A EP1716128B1 (de) 2004-02-11 2005-02-11 Substituierte 4,5,6,7-tetrahydro-benzothiazol-2-ylamin-verbindungen

Publications (1)

Publication Number Publication Date
CY1110156T1 true CY1110156T1 (el) 2015-01-14

Family

ID=34813281

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100582T CY1110156T1 (el) 2004-02-11 2010-06-25 Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης

Country Status (13)

Country Link
US (1) US7348347B2 (el)
EP (1) EP1716128B1 (el)
JP (1) JP5016312B2 (el)
AT (1) ATE462699T1 (el)
CA (1) CA2555595C (el)
CY (1) CY1110156T1 (el)
DE (2) DE102004006808A1 (el)
DK (1) DK1716128T3 (el)
ES (1) ES2343735T3 (el)
PL (1) PL1716128T3 (el)
PT (1) PT1716128E (el)
SI (1) SI1716128T1 (el)
WO (1) WO2005077924A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
GB0712101D0 (en) * 2007-06-22 2007-08-01 Therapeutics Ltd E Treatment of depression
GB0811024D0 (en) * 2008-06-17 2008-07-23 E Therapeutics Plc Sustained release treatment of depression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
FR2658823B1 (fr) * 1990-02-27 1992-04-30 Adir Nouveaux derives d'aminomethylpiperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent .
FR2681325B1 (fr) * 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5712270A (en) * 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
HUP0102101A3 (en) * 1997-11-10 2002-11-28 Bristol Myers Squibb Co Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them
EP1242072A4 (en) * 1999-12-17 2004-02-04 Bristol Myers Squibb Co ANTIPSYCHOTIC HETEROCYCLIC COMPOUNDS
GB0114185D0 (en) * 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds

Also Published As

Publication number Publication date
US7348347B2 (en) 2008-03-25
PL1716128T3 (pl) 2010-09-30
DE502005009310D1 (de) 2010-05-12
DK1716128T3 (da) 2010-07-26
ATE462699T1 (de) 2010-04-15
PT1716128E (pt) 2010-07-06
JP5016312B2 (ja) 2012-09-05
WO2005077924A1 (de) 2005-08-25
ES2343735T3 (es) 2010-08-09
EP1716128A1 (de) 2006-11-02
JP2007522171A (ja) 2007-08-09
DE102004006808A1 (de) 2005-09-01
SI1716128T1 (sl) 2010-08-31
CA2555595C (en) 2013-10-29
US20070027315A1 (en) 2007-02-01
EP1716128B1 (de) 2010-03-31
CA2555595A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
ATE414089T1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA200802213A1 (ru) Способы лечения заболеваний крови
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
DE502005008058D1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
ATE433447T1 (de) Pyrimiidinverbindungen
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
EA200870569A1 (ru) Соединения и способы модуляции fxr
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
ATE457027T1 (de) Substituierte 1,4,8-triazaspiroä4.5 decan-2-on- verbindungen zur behandlung von fettsucht
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
DE602004017037D1 (de) 2,3-dihydro-6-nitroimidazoä2,1-büoxazolverbindungen zur behandlung von tuberkulose
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE602004024871D1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer